FindTrial
Sign In

Advanced prenatal screening in the first trimester of pregnancy: ADAM12 and PP13 as new screening markers for aneuploidy and adverse pregnancy outcome.

Advanced prenatal screening in the first trimester of pregnancy: ADAM12 and PP13 as new screening markers for aneuploidy and adverse pregnancy outcome. - ADAM12 and PP13 in first trimester of pregnancy.

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON31468
Enrollment
20000
Registered
2008-05-23
Start date
2008-07-01
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Down syndrome Trisomy 21

Interventions

None listed

Sponsors

Vrije Universiteit Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Pregnant, singleton Between 8-10 weeks gestation.

Exclusion criteria

Exclusion criteria: Multiple pregnancies. Gestation more than 10 weeks.

Design outcomes

Primary

MeasureTime frame
The goal of this study is to determine differences in screening performance expressed as detection rate (DR), false positive rate (FPR) and odds of being affected given a positive result (OAPR). This will be analysed for the combined test with and without ADAM-12.—

Secondary

MeasureTime frame
Attention will be given to the fact if ADAM12 and PP13 have predictive value for adverse pregnancy outcome.—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)